ArticleBlood2022
Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib.
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Single-cell epigenetic and transcriptomic states across the continuum of monoclonal B cell lymphocytosis to chronic lymphocytic leukemia.Genome biology · 2026Article
- Concurrent CML and MBL in a COPD patient: a case of collision hematologic malignancies and opportunistic infection.Frontiers in medicine · 2026Article
- Single-cell insights into the role of T cells in B-cell malignancies.FEBS letters · 2025Review
- State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee.Blood cancer journal · 2025Article
- Fatty acid metabolism shapes immune responses in chronic lymphocytic leukemia.Biomarker research · 2025Article
- Leveraging the Immunomodulatory Potential of Ibrutinib for Improved Outcomes of T Cell-Mediated Therapies of B Cell Malignancies: A Narrative Review.Targeted oncology · 2025Review
- The rewired immune microenvironment in leukemia.Nature immunology · 2025Review
- Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.Journal of hematology & oncology · 2025Review
- West Nile Virus Encephalitis in a Patient with Chronic Lymphocytic Leukemia.Mediterranean journal of hematology and infectious diseases · 2025Article
- Decoding leukemia at the single-cell level: clonal architecture, classification, microenvironment, and drug resistance.Experimental hematology & oncology · 2024Review
- Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy.Cureus · 2024Review
- T Cell-intrinsic Immunomodulatory Effects of TAK-981 (Subasumstat), a SUMO-activating Enzyme Inhibitor, in Chronic Lymphocytic Leukemia.Molecular cancer therapeutics · 2023Article
- The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia.Blood · 2023Review
- Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.Frontiers in immunology · 2022Review
Corrections and comments
- Commented on by
Authors and funding
22 authors at 9 institutions in 5 countries.
Noelia PurroyDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
Yuzhou Evelyn TongHarvard Medical School, Boston, MA.
Camilla K LemvighDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.ORCID 0000-0002-5772-8743
Nicoletta CieriDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.ORCID 0000-0003-1340-6272
Shuqiang LiBroad Institute, Cambridge, MA.
Erin M ParryDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3382-9769
Wandi ZhangDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
Laura Z RassentiMoores Cancer Center, University of California San Diego, La Jolla, CA.
Thomas J KippsMoores Cancer Center, University of California San Diego, La Jolla, CA.
Susan L SlagerDepartment of Health Sciences Research and.
Neil E KayDepartment of Health Sciences Research and.ORCID 0000-0002-5951-5055
Connie LesnickDepartment of Medicine, Mayo Clinic, Rochester, MN.
Tait D ShanafeltDepartment of Medicine, Stanford University, Stanford, CA.
Paolo GhiaDivision of Experimental Oncology, Department of Onco-Hematology, Università Vita-Salute San Raffaele-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan Italy.ORCID 0000-0003-3750-7342
Lydia ScarfòDivision of Experimental Oncology, Department of Onco-Hematology, Università Vita-Salute San Raffaele-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale San Raffaele, Milan Italy.
Kenneth J LivakDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.ORCID 0000-0001-9105-5856
Peter V KharchenkoDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA.
Donna S NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Lars Rønn OlsenProgram in Health Sciences and Technology, Harvard Medical School-Massachusetts Institute of Technology, Boston, MA.ORCID 0000-0002-6725-7850
Jean FanDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD.ORCID 0000-0002-0212-5451
Satyen H GohilDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.
Catherine J WuDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA.ORCID 0000-0002-3348-5054
Broad Institute · USDana-Farber Cancer Institute · USHarvard University · USMayo Clinic in Arizona · USUniversity of California San Diego · USVita-Salute San Raffaele University · ITDepartment of Medical Sciences · BYJohns Hopkins University · USStanford University · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MTissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MITSC for Leukemia: Novel Molecular strategies for NCTN "Individualized" TherapiesUG1CA233338 · NCI · UNIVERSITY OF CINCINNATI · PI BYRD, JOHN C. · 2019 to 2025
$4.5M(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemiaR01CA216273 · NCI · DANA-FARBER CANCER INST · PI WANG, LILI, WU, CATHERINE JU-YING · 2017 to 2021
$3.5MComputational methods for delineating subcellular and cellular spatial transcriptional heterogeneity along developmental trajectoriesR35GM142889 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI FAN, JEAN · 2021 to 2025
$2.0MSingle cell investigation of co-evolution in cancer cells and host cell immune microenvironmentR50CA251956 · NCI · DANA-FARBER CANCER INST · PI Shuqiang Li · 2020 to 2026
$1.4MNCI NIH HHS P01 CA081534NCI NIH HHS P01 CA206978NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA216273NCI NIH HHS R50 CA251956NCI NIH HHS UG1 CA233338NIGMS NIH HHS R35 GM142889
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellAdenineHumansPiperidinesProtein Kinase InhibitorsSingle-Cell AnalysisAdenineibrutinibPiperidinesProtein Kinase Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.